Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes

Journal of Cardiac Failure

Volumn 21, Issue 1, 2015, Pages 2-8

  Velez, Mauricio ^a   Peterson, Edward L ^a   Wells, Karen ^a   Swadia, Tanmay ^a   Sabbah, Hani N ^a   Williams, L Keoki ^a   Lanfear, David E ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

DPP 4 inhibitor; GLP 1 agonist; heart failure; outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EXPOSURE; DRUG TARGETING; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; AGED; AGONISTS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; METABOLISM; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TRENDS;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DELIVERY SYSTEMS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84919625052     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.10.012     Document Type: Article

References (35)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, and W.B. Borden Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association Circulation 125 2012 188 197
2. V.L. Roger, S.A. Weston, M.M. Redfield, J.P. Hellermann-Homan, J. Killian, and B.P. Yawn Trends in heart failure incidence and survival in a community-based population JAMA 292 2004 344 350
3. W.B. Kannel, M. Hjortland, and W.P. Castelli Role of diabetes in congestive heart failure: the Framingham study Am J Cardiol 34 1974 29 34
4. A. Azevedo, P. Bettencourt, P.B. Almeida, A.C. Santos, C. Abreu-Lima, and H.W. Hense Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities-cross-sectional study of the general population BMC Cardiovasc Disord 7 2007 17
5. E. Ingelsson, J. Arnlöv, L. Lind, and J. Sundström Metabolic syndrome and risk for heart failure in middle-aged men Heart 92 2006 1409 1413
6. M. Domanski, H. Krause-Steinrauf, P. Deedwania, D. Follmann, J.K. Ghali, and E. Gilbert The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial J Am Coll Cardiol 42 2003 914 922
7. D.L. Dries, N.K. Sweitzer, M.H. Drazner, L.W. Stevenson, and B.J. Gersh Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction J Am Coll Cardiol 38 2001 421 428
8. M. Guazzi, R. Brambilla, G. Pontone, P. Agostoni, and M.D. Guazzi Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure Am J Cardiol 89 2002 191 197
9. M.H. Davidson Cardiovascular effects of glucagonlike peptide-1 agonists Am J Cardiol 108 3 Suppl 2011 33B 41B
10. Q. Liu, C. Anderson, A. Broyde, C. Polizzi, R. Fernandez, and A. Baron Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure Cardiovasc Diabetol 9 2010 76
11. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, and D. Elahi Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
12. D. Nathanson, B. Ullman, U. Löfström, A. Hedman, M. Frick, and Å. Sjöholm Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety Diabetologia 55 2012 926 935
13. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
14. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
15. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 2013 1327 1335
16. F. Alqaisi, L.K. Williams, E.L. Peterson, and D.E. Lanfear Comparing methods for identifying patients with heart failure using electronic data sources BMC Health Serv Res 9 2009 237
17. W.Y. Lee, A.M. Capra, N.G. Jensvold, J.H. Gurwitz, and A.S. Go Gender and risk of adverse outcomes in heart failure Am J Cardiol 94 2004 1147 1152
18. T.S. Wang, A.S. Hellkamp, C.B. Patel, J.A. Ezekowitz, G.C. Fonarow, and A.F. Hernandez Representativeness of RELAX-AHF clinical trial population in acute heart failure Circ Cardiovasc Qual Outcomes 7 2014 259 268
19. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
20. S. Ravassa, A. Zudaire, and J. Diez GLP-1 and cardioprotection: from bench to bedside Cardiovasc Res 94 2012 316 323
21. L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, and L. Zourelias Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
22. I. Poornima, S.B. Brown, S. Bhashyam, P. Parikh, H. Bolukoglu, and R.P. Shannon Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat Circ Heart Fail 1 2008 153 160
23. A.K. Vyas, K.C. Yang, D. Woo, A. Tzekov, A. Kovacs, and P.Y. Jay Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy PLoS One 6 2011 e17178
24. G.G. Sokos, H. Bolukoglu, J. German, T. Hentosz, G.J. Magovern Jr., and T.D. Maher Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting Am J Cardiol 100 2007 824 829
25. P.A. Read, S.P. Hoole, P.A. White, F.Z. Khan, M. O'Sullivan, and N.E. West A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans Circ Cardiovasc Interv 4 2011 266 272
26. J. Lonborg, N. Vejlstrup, H. Kelbaek, H.E. Botker, W.Y. Kim, and A.B. Mathiasen Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 1491 1499
27. J.H. Best, B.J. Hoogwerf, W.H. Herman, E.M. Pelletier, D.B. Smith, and M. Wenten Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the Lifelink database Diabetes Care 34 2011 90 95
28. O.E. Johansen, D. Neubacher, M. von Eynatten, S. Patel, and H.J. Woerle Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 11 2012 3
29. D. Wu, L. Li, and C. Liu Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis Diabetes Obes Metab 16 2014 30 37
30. M. Monami, F. Cremasco, C. Lamanna, C. Colombi, C.M. Desideri, and I. Iacomelli Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials Exp Diabetes Res 2011 2011 215764
31. R. Ratner, J. Han, D. Nicewarner, I. Yushmanova, B.J. Hoogwerf, and L. Shen Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes Cardiovasc Diabetol 10 2011 22
32. F. Sun, K. Yu, S. Wu, Y. Zhang, Z. Yang, and L. Shi Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis Diabetes Res Clin Pract 98 2012 386 395
33. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/home. Accessed August 23, 2013.
34. L.K. Williams, C.L. Joseph, E.L. Peterson, C. Moon, H. Xi, and R. Krajenta Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids J Allergy Clin Immunol 119 2007 168 175
35. Z.A. Habib, S.L. Havstad, K. Wells, G. Divine, M. Pladevall, and L.K. Williams Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 95 2010 592 600